2014

Exagen Diagnostics Names Robert Mignatti President and Chief Operating Officer

    ALBUQUERQUE, N.M., Jan. 24 /PRNewswire/ -- Exagen Diagnostics, Inc., which
 develops and commercializes genomic marker-based in vitro diagnostic (IVD)
 kits for prognosis and prediction of treatment response, today announced that
 Robert Mignatti has joined the company as president and COO. He oversees
 Exagen's day-to-day operations, as well as company alliances. Exagen CEO Jim
 McClintic, who joined the company in October, will continue to guide the
 company's strategic direction.
     "Our mission is to focus innovative genomic and computational science on
 creating leading-edge markers and tests that individualize patient care
 worldwide," said McClintic. "Bob's expertise in business development and
 planning, strategic partnerships and acquisitions, and developing key
 personnel makes him a very strong asset as we build the management team that
 will elevate Exagen to its next phase of growth."
     Mignatti comes to Exagen with 33 years of laboratory and kit-based
 diagnostics experience, including senior management and sales roles at
 Esoterix, Inc., Allergy Testing Laboratory, Kallestad Diagnostics, Inc. and
 Baxter International. At Esoterix, which provides specialty value-added
 laboratory testing information services, Mignatti served as executive vice
 president and COO, working directly with McClintic for the past five years.
 Last year, McClintic and Mignatti led the sale of Esoterix to LabCorp, Inc.
 for $150 million.
     "This is an exciting business opportunity because Exagen will be launching
 the first IVD kits to detect changes in DNA copy number in tumor tissue to
 predict risk of recurrence for both hormone receptor (HR)-positive and
 HR-negative breast cancer patients," said Mignatti. "It's also a privilege to
 help lead the commercialization of a scientific advancement that has the
 potential to significantly improve the quality of life for people with serious
 diseases."
 
     About Exagen Diagnostics, Inc.
     As an emerging leader in the development of prognostic and predictive in
 vitro diagnostic (IVD) kits, Exagen Diagnostics is uniquely able to discover,
 validate and productize small sets of genomic markers for use in oncology,
 infectious disease and other indications. Exagen aims to commercialize IVD
 kits that can be performed by existing diagnostic laboratories and to develop
 tests that accompany the launch of new therapeutics and/or support
 pharmaceutical R&D/Phase IV. For more information, visit
 http://www.exagendiagnostics.com.
 
 

SOURCE Exagen Diagnostics, Inc.

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.